Clinical Trial

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To evaluate the safety, tolerability, and preliminary efficacy of JS111 capsules in patients with locally advanced, metastatic, or recurrent NSCLC harboring EGFR mutations;to determine the recommended Phase II dose (RP2D).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-15; most recent amendment 2026-07-02.
Status change: Recruiting → Active, Not Recruiting 2026-07-02
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06940401
Lead Sponsor Suzhou Junjing BioSciences Co., Ltd.
Collaborators: Sponsor GmbH
Conditions NSCLC
Enrollment 44 participants
Start Date 2025-04-30
Primary Completion 2028-07-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07